Published in Blood Cells Mol Dis on June 29, 2004
Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature (2012) 2.25
Batf3 maintains autoactivation of Irf8 for commitment of a CD8α(+) conventional DC clonogenic progenitor. Nat Immunol (2015) 1.23
Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival. Blood (2008) 1.16
Light control of plasma membrane recruitment using the Phy-PIF system. Methods Enzymol (2011) 1.14
Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat Protoc (2012) 1.03
A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery. MAbs (2011) 0.78
Aberrant epigenetic regulators control expansion of human CD34+ hematopoietic stem/progenitor cells. Front Genet (2013) 0.75
UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem (2002) 3.52
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J (2006) 2.84
Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol Cell Biol (2004) 2.70
Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med (2004) 2.59
Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol (2011) 2.51
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med (2006) 2.36
Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev (2003) 2.24
High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem (2003) 2.24
The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem (2005) 2.19
The 8;21 translocation in leukemogenesis. Oncogene (2004) 2.18
Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem Biophys Res Commun (2005) 2.18
Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res (2010) 2.14
RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells. Blood (2013) 2.00
ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J Biol Chem (2008) 1.98
ISG15: the immunological kin of ubiquitin. Semin Cell Dev Biol (2004) 1.87
Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol (2006) 1.80
Mice lacking the ISG15 E1 enzyme UbE1L demonstrate increased susceptibility to both mouse-adapted and non-mouse-adapted influenza B virus infection. J Virol (2008) 1.73
Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol (2009) 1.61
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci U S A (2004) 1.60
ISG15: a ubiquitin-like enigma. Front Biosci (2005) 1.58
ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. Genes Dev (2007) 1.57
Regulation of Rap2A by the ubiquitin ligase Nedd4-1 controls neurite development. Neuron (2010) 1.57
Dysregulation of protein modification by ISG15 results in brain cell injury. Genes Dev (2002) 1.57
Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool. Blood (2011) 1.54
SON controls cell-cycle progression by coordinated regulation of RNA splicing. Mol Cell (2011) 1.52
Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential. Blood (2013) 1.46
Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia. Blood (2012) 1.42
Enhanced antibacterial potential in UBP43-deficient mice against Salmonella typhimurium infection by up-regulating type I IFN signaling. J Immunol (2005) 1.42
RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci (Landmark Ed) (2012) 1.37
Different roles for two ubiquitin-like domains of ISG15 in protein modification. J Biol Chem (2008) 1.31
ISG15 modification of filamin B negatively regulates the type I interferon-induced JNK signalling pathway. EMBO Rep (2009) 1.30
Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood (2007) 1.29
ISG15, not just another ubiquitin-like protein. Biochem Biophys Res Commun (2003) 1.29
Lipopolysaccharide activates the expression of ISG15-specific protease UBP43 via interferon regulatory factor 3. J Biol Chem (2002) 1.25
AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol Cell Biol (2006) 1.18
MicroRNA programs in normal and aberrant stem and progenitor cells. Genome Res (2011) 1.17
ISG15 modification of ubiquitin E2 Ubc13 disrupts its ability to form thioester bond with ubiquitin. Biochem Biophys Res Commun (2005) 1.17
The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood (2007) 1.17
AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. PLoS Genet (2008) 1.17
Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival. Blood (2008) 1.16
Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci U S A (2008) 1.14
The level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression. J Immunol (2008) 1.10
The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Mol Cell Biol (2005) 1.08
t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. Blood (2008) 1.07
PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Blood (2012) 1.07
USP18 inhibits NF-κB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex. J Exp Med (2013) 1.02
Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood (2007) 1.02
Negative regulation of ISG15 E3 ligase EFP through its autoISGylation. Biochem Biophys Res Commun (2007) 1.02
RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. Blood (2008) 1.02
Microarray analysis reveals that Type I interferon strongly increases the expression of immune-response related genes in Ubp43 (Usp18) deficient macrophages. Biochem Biophys Res Commun (2007) 0.99
Usp18 driven enforced viral replication in dendritic cells contributes to break of immunological tolerance in autoimmune diabetes. PLoS Pathog (2013) 0.99
Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10. EMBO Mol Med (2013) 0.99
Evidence for annexin II-S100A10 complex and plasmin in mobilization of cytokine activity of human TrpRS. J Biol Chem (2007) 0.99
UBP43, an ISG15-specific deconjugating enzyme: expression, purification, and enzymatic assays. Methods Enzymol (2005) 0.99
Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome. Blood (2012) 0.97
Increased cerebral protein ISGylation after focal ischemia is neuroprotective. J Cereb Blood Flow Metab (2011) 0.95
The ISG15 isopeptidase UBP43 is regulated by proteolysis via the SCFSkp2 ubiquitin ligase. J Biol Chem (2004) 0.95
Expression of AML/Runx and ETO/MTG family members during hematopoietic differentiation of embryonic stem cells. Exp Hematol (2007) 0.93
Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML. Blood (2012) 0.92
Two independent mechanisms promote expression of an N-terminal truncated USP18 isoform with higher DeISGylation activity in the nucleus. J Biol Chem (2011) 0.92
Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release. Nanomedicine (Lond) (2013) 0.92
Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model. EMBO Mol Med (2013) 0.92
Activation of double-stranded RNA-activated protein kinase (PKR) by interferon-stimulated gene 15 (ISG15) modification down-regulates protein translation. J Biol Chem (2012) 0.91
RUNX1 regulates the CD34 gene in haematopoietic stem cells by mediating interactions with a distal regulatory element. EMBO J (2011) 0.90
SON protein regulates GATA-2 through transcriptional control of the microRNA 23a~27a~24-2 cluster. J Biol Chem (2013) 0.89
Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale (2013) 0.89
A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy. Blood (2006) 0.87
Retinoic acid-induced protein ISGylation is dependent on interferon signal transduction. Blood Cells Mol Dis (2006) 0.86
Ubp43 gene expression is required for normal Isg15 expression and fetal development. Reprod Biol Endocrinol (2007) 0.84
Nitrosylation of ISG15 prevents the disulfide bond-mediated dimerization of ISG15 and contributes to effective ISGylation. J Biol Chem (2008) 0.83
Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse. Eur J Haematol (2009) 0.83
Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO. Blood Cells Mol Dis (2007) 0.82
Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association. Mol Cancer Res (2005) 0.82
Usp18 promotes conventional CD11b+ dendritic cell development. J Immunol (2012) 0.82
AML1-FOG2 fusion protein in myelodysplasia. Blood (2005) 0.81
Isoforms of the Ets transcription factor NERF/ELF-2 physically interact with AML1 and mediate opposing effects on AML1-mediated transcription of the B cell-specific blk gene. J Biol Chem (2004) 0.81
Hematopoietic cells from Ube1L-deficient mice exhibit an impaired proliferation defect under the stress of bone marrow transplantation. Blood Cells Mol Dis (2010) 0.81
ISG15 modulates development of the erythroid lineage. PLoS One (2011) 0.80
Alteration of tumor spectrum by ISGylation in p53-deficient mice. Cancer Biol Ther (2009) 0.80
The mitochondrial pathway and reactive oxygen species are critical contributors to interferon-α/β-mediated apoptosis in Ubp43-deficient hematopoietic cells. Biochem Biophys Res Commun (2012) 0.79
Deficiency of a potential 3p21.3 tumor suppressor gene UBE1L (UBA7) does not accelerate lung cancer development in K-rasLA2 mice. Lung Cancer (2008) 0.78
p53 alterations in myeloid leukemia. Acta Haematol (2004) 0.78
Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia. PLoS Genet (2013) 0.77
Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis. Blood Cells Mol Dis (2007) 0.77
SERPINB13 is a novel RUNX1 target gene. Biochem Biophys Res Commun (2011) 0.76
ISG15 regulates IFN-γ immunity in human mycobacterial disease. Cell Res (2012) 0.76
Response: the role of RUNX1 isoforms in hematopoietic commitment of human pluripotent stem cells. Blood (2013) 0.75
Murine Herc6 Plays a Critical Role in Protein ISGylation In Vivo and Has an ISGylation-Independent Function in Seminal Vesicles. J Interferon Cytokine Res (2014) 0.75
RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development. Leuk Lymphoma (2013) 0.75